Original Editors - Anna Marie Usery & Stephanie Wilton from Bellarmine University's Pathophysiology of Complex Patient Problems project.
- 1 Definition/Description
- 2 Prevalence
- 3 Characteristics/Clinical Presentation
- 4 Clinical Staging for Cervical Cancer
- 5 Associated Co-morbidities
- 6 Medications
- 7 Diagnostic Tests/Lab Tests/Lab Values
- 8 Etiology/Causes
- 9 Systemic Involvement
- 10 Medical Management
- 11 Physiotherapy Management (Current Best Evidence)
- 12 Differential Diagnosis
- 13 Resources
- 14 References
Cervical cancer is a type of cancer that forms within the tissues of the cervix. The cervix connects the uterus with the vagina (birth canal)., The endocervix is the portion of the cervix closest to the uterus whereas the exocervix or ectocervix is closest to the vagina. The cervix is covered in two main types of cells: squamous cells found on the exocervix, and glandular cells on the endocervix. Squamous and glandular cells come together at the area known as the transformation zone. It is here where most cervical cancers originate. Gradually, the normal cells lining this area develop pre-cancerous changes that transform into cancer. Cervical cancer typically grows at a slow rate and presents asymptomatically. Therefore, it is recommended to receive routine Papanicolaou (Pap) smears to test for changes in the lining of the cervix and/or the development of cancerous cells.
In the United States, cervical cancer is the fourteenth most common type of cancer found in women and the third most common gynecological malignancy., However worldwide, cervical cancer is the most commonly found type of cancer in women. In the United States, the diagnosis of invasive stage cervical cancer has declined (75% decline since the 1960s) steadily.Screening for cervical cancer has become more common due to the introduction of the Pap smear in the 1930s which made early detection possible. Although cervical cancer is the most common cause of gynecological cancer-related death worldwide, mortality rates have decreased significantly in the United States (more than 45% since the early 1970s).,
In the United States, approximately 11,000 women are diagnosed with cervical cancer and 3,700 women die due to the disease each year. Worldwide, nearly 500,000 women are diagnosed with cervical cancer annually. The disease accounts for 288,000 deaths per year.
80% to 85% of cervical cancer-related deaths occur in developing countries.
Pre-invasive carcinoma in situ (no invasion of surrounding tissues) is more common in women 30-40 years of age. Invasive carcinoma is more frequent in women over 40 years of age. Women ages 65 and over account for 25% of new cases of cervical cancer.
- May be asymptomatic (early stages)
- Painful intercourse or pain after intercourse
- Unexplained or unexpected bleeding (after intercourse or between menstrual periods),
- Watery, foul-smelling vaginal discharge (serosanguineous or yellowish color),
- Pelvic, epigastric, or low back pain (with large lesions),
- Hemiparesis, headache (cancer recurrence with brain metastases)
- Bowel and bladder problems (later stages)
Clinical Staging for Cervical Cancer
Cervical cancer is staged by the International Federation of Gynecology and Obstetrics (FIGO) staging system, based on clinical examination rather than surgical findings. For premalignant dysplastic changes, cervical intraepithelial neoplasia (CIN) grading is used.
*If the woman is treated surgically, the pathology report can be used to provide a separate pathologic stage; this does not replace the original clinical stage.
||Full-thickness involvement of the epithelium (surface) without invasion into the stroma (support structure); carcinoma in situ (CIN grades 1, 2, or 3 are assigned)|
||Invaded the cervix but has not spread any further|
||Small enough it can only be diagnosed by microscopy; there are no visible lesions|
||IA1||Area of invasion is less than 3 millimeters (1/8-inch) deep and less than 7 millimeters (1/4-inch) wide|
||IA2||Area of invasion is between 3 and 5 millimeters (about 1/5-inch) with horizontal spread of 7 millimeters or less|
||Visible lesion or a microscopic lesion with more than 5 millimeters of depth or horizontal spread of more than 7 millimeters; has spread into connective tissue of the cervix|
||IB1||Visible lesion 4 centimeters or less in greatest dimension|
||IB2||Visible lesion more than 4 centimeters|
||Invades beyond cervix to upper 1/3 of the vagina only|
||Without parametrial (tissue next to the cervix) invasion|
||With parametrial invasion|
||Extends to pelvic wall or lower 1/3 of the vagina|
||Involves lower 1/3 of vagina but not the pelvic wall|
||Extends to pelvic wall and/or blocks urine flow to the bladder; may have spread to pelvic lymph nodes|
||Extends beyond the true pelvis|
||Invades mucosa of bladder or rectum and/or extends beyond true pelvis|
||Distant metastasis to other organs (beyond the pelvis) such as lungs|
Cervical cancer is associated with and may be the manifestation of human papillomavirus (HPV).
Drugs Approved to Prevent Cervical Cancer
- Cervarix (Recombinant HPV Bivalent Vaccine)
- Gardasil (Recombinant HPV Quadrivalent Vaccine)
-Gardasil protects against two strains of HPV that cause cervical cancer. The vaccine is administered to females between the ages of 9 and 26. The vaccination is especially important for women who do not have access to regular cervical cancer screenings.
Drugs Approved to Treat Cervical Cancer
*Systemic chemotherapy involves injecting or orally administering cancer-treating drugs. These drugs then enter the bloodstream, and travel throughout the body, reaching areas of cancerous growth.Chemotherapy can work in the following ways:
-Cure the cancer
-Shrink the cancer
-Prolong life span by controlling cancer or putting it into remission
- Blenoxane (Bleomycin)-mixture of cytotoxic glycopeptide antibiotics; Side effects- pulmonary fibrosis, hypotension, mental confusion, fever, chills and wheezing.
- Cisplatin*-sterile aqueous solution that contains sodium chloride in water for injection; Side effects- renal toxicity, nausea and vomitting, myelo-suppression, ototoxicity, facial edema, bronchoconstriction, tachycardia, hypotension
- Hycamtin (Topotecan Hydrochloride)- antitumor drug with topoisomerase 1-inhibitory activity
- Platinol (Cisplatin)
- Platinol-AQ (Cisplatin)
- Topotecan Hydrochloride (Hycamtin)
- Paclitaxel* (Taxol)- nonaqueous solution with antitumor activity; Side effects- anaphylaxis, dyspnea, hypotension, angioedema, urticaria (hives)
- Gemcitabine (Gemzar)-nucleoside metabolic inhibitor that exhibits antitumor activity; Side effects- pallor, easy bruising or bleeding, unusual weakness, decreased urination, nausea, upper stomach pain, dark urine, clay-colored stools, jaundice, chest pain, pain spreading to arm or shoulder, diaphoresis, signs of allergic reaction
*Currently, Cisplatin is the most effective single chemotherapy drug for recurrent disease. When administered with paclitaxel, the combination is more effective than cisplatin alone (in terms of response rate and survival).
Drug Combinations Used in Cervical Cancer
Diagnostic Tests/Lab Tests/Lab Values
Medical professionals who are able to diagnose cervical cancer include:
- Family physicians
- Nurse practitioner
- Physican assistants
A Pap smear, also referred to as a Pap test, tests cervical cells for abnormal changes. It is these abnormal cellular changes that can lead to cervical cancer if left untreated. Cervical cancer is highly preventable, given that regular Pap smears are performed. It is recommended that women receive annual Pap smears beginning three years after the onset of vaginal intercourse but no later than 21 years of age. Women aged 70 and older, with an intact cervix, are no longer required to recevie Pap smears if they have had no positive test results within the last 10 years. Women who do not have a cervix (ex. hysterectomy), as well as no history of abnormal Pap results or cervical cancer can discontinue annual Pap smears. However, some medical professionals support routine Pap smears regardless of age, presence of cervix, or past negative test results. Even if not currently sexually active, or protected sex is being practiced, regular Pap smears should still be performed.
*Tumor must be at least stage 1b or greater to be seen on a radiograph.
- Magnetic resonance imaging (MRI)- imaging modality of choice for depicting primary tumor
- Ultrasound- tumor appears as a hypoechoic (dark) cervical mass; should not be used as a primary diagnostic tool
- Computed tomography (CT)-used to assess disease in more advanced stages and/or monitor distant metastasis
- Positron emission tomography (PET)-CT- imaging modality of choice for staging cervical cancer
- Endocervical curettage (scraping)
The presence of HPV is a common feature in the majority of individuals diagnosed with cervical cancer. Clinical studies show that the transference of HPV during unprotected sexual intercourse is the primary cause of cervical cancer. The disease can spread through local extension and through the lymphatic system to the retroperitoneal lymph nodes.
- Early age at first sexual intercourse (17 years or younger)
- Early age at first pregnancy
- Tobacco use, including exposure to passive smoke
- Low socioeconomic status (lack of screening)
- History of any sexually transmitted disease (STD), especially HPV and human immunodeficiency virus (HIV)
- History of multiple sex partners (five or more)
- History of childhood sexual abuse
- Intimate partner abuse
- Women whose mothers used the drug diethylstilbestrol (DES) during pregnancy
- Hormonal contraceptive use
- Ethnic background- African-American women experience a 72% higher incidence compared with Caucasian women
- High parity (number of births)
- Alcohol and drug use (impaired decision making)
Cervical cancer affects the female reproductive system.
Pressure from tumor on neighboring structures can affect the urinary system and gastrointestinal system (bowel).
Metastasis has been known to occur to the central nervous system (CNS), pulmonary system, urinary system (bladder), gastrointestinal system (rectum), retroperitoneal lymph nodes, paracervical lymphatics and parametrial lymphatics.
The treatment of cervical cancer varies depending on clinical staging.
Recommended Treatment Based on Clinical Staging for Cancer of the Cervix
|| Cryosurgery, laser surgery, loop electrosurgical excision procedure (LEEP), electrocautery|
|| LEEP, laser surgery, conization, cryosurgery, radiation without surgery, total hyterectomy with or without bilateral pelvic lymphadenectomy|
|| Radiation, radical hysterectomy and pelvic lymphadenectomy often followed by radiation|
|| Radiation with external beam or implant(s) with or without hydroxyurea |
|| Radiation with external beam or implant(s) with or without hydroxyurea, chemotherapy (cisplatin or ifosfamide with distant site involvement)|
Recent findings have shown that women staged with CIN 2 or 3 may not require immediate treatment, as the abnormality may regress naturally.
Previous research has shown that cisplatin-based chemotherapy combined with radiation has increased survival rates in women with locally advanced cervical cancer.
Recently, new research has been conducted to determine the effectiveness of concurrent cisplatin-based chemotherapy with an epidermal growth factor receptor inhibitor (E). Epidermal growth factor receptor (EGFR) is commonly overexpressed in cervical cancer; therefore, the inhibitor, which has antitumor effects, acts to decrease the expression of EGFR. The results of this study suggest that treatment with E combined with cisplatin-based chemotherapy has been shown to work against a locally advanced cervical cancer.
Physiotherapy Management (Current Best Evidence)
The primary role of physical therapy associated with cervical cancer is education. Physiotherapists should be an advocate to their patients to stay regular with Pap smears and to practice other preventative measures (physical examinations, vaccines, protected sex). It is important for physiotherapists to gather a thorough patient history, including questions that encompass issues such as vaginal bleeding, GI or genitourinary function, location of pain and discomfort, and pre-existing comorbidities. If issues of concern are found during the evaluation, physiotherapists should refer the patient to their primary care physician for further testing.
physiotherapists should look for signs and symptoms of metastasis in women with a previous history of cervical cancer. Lymph node palpation is an important component of the examination due to the high rate of metastasis to this location. Questions that address possible warning signs of metastasis (ex. rapid weight loss, night pain/sweats, vaginal bleeding, fatigue, frequent infections) should be included in patient history. If issues of concern are found during the evaluation, physiotherapists should refer the patient to their primary care physician for further testing.
Women who have a current diagnosis of cervical cancer can benefit from physical therapy services. Physical therapy provides symptom relief by addressing impairments such as fatigue, muscle weakness, and management of pain.
While treating patients with cancer, it is important for physiotherapists to review hematological values. Aerobic exercise is contraindicated for patients receiving chemotherapy treatments when lab values are as follows:
|White blood cell count||<3,000/mm3|
In an outpatient setting, it is recommended for physiotherapists to monitor vital signs and rate of perceived exertion (RPE) during exercise when working with patients with cancer.
Local Vaginal Treatment of the Cervix
- Escharotic treatment- This plant and mineral-based extract is applied to the surface of the cervix. It contains proteolytic properties that dissolve the top layer of cervical cells, which are affected by the HPV virus.
- Vaginal suppository treatment- Vag pak acts to enhance the immune system and rid cervical cells of infection.
- Cervical conditions (infections, polyps, myomas)
- Iatrogenic (birth control pills, HRT, IUD)
- Cervical ectopic pregnancy (consider with women of childbearing age)
- Endometrial cancer with cervical invasion
- Other cervical malignant condition (sarcoma, lymphoma, metastasis)
- Invasion of the cervix from other organs in proximity:
- Bladder cancer
- Rectal cancer
- Vaginal cancer
- Uterine cancer
National Institue of Cancer, Cervical Cancer: http://www.cancer.gov/
American Cancer Society, Cervical Cancer: http://www.cancer.org/
NC Cervical Cancer Resource Directory: http://www.ccresourcedirectory.org/
- Available at: http://www.cancer.gov/cancertopics/types/cervical. Accessed March 18, 2014.
- Available at: http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-what-is-cervical-cancer. Accessed March 18, 2014.
- Ph.d. SE, Ph.d. KL. Understanding Pathophysiology. Mosby Incorporated; 2011.
- Goodman CC, Snyder TE. Differential Diagnosis for Physical Therapists, Screening for Referral. W B Saunders Company; 2012.
- Reviews CT. e-Study Guide for: Pathology: Implications for the Physical Therapist by Catherine C. Goodman, ISBN 9781416031185. Cram101 Textbook Reviews; 2012.
- Available at: http://www.rho.org/about-cervical-cancer.htm. Accessed March 18, 2014.
- Available at: http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment/chemotherapy-principles-types-of-chemo-drugs. Accessed March 19, 2014.
- Available at: http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/chemotherapy/about/how-chemotherapy-works. Accessed March 18, 2014.
- Available at: http://www.rxlist.com/script/main/hp.asp. Accessed March 19, 2014.
- Cervical cancer. The Lancet. 2003;361(9376):2217.
- Available at: http://www.webmd.com/cancer/cervical-cancer/cervical-cancer-when-to-call-a-doctor. Accessed March 19, 2014.
- Available at: http://www.womenshealth.gov/publications/our-publications/fact-sheet/pap-test.html. Accessed March 20, 2014.
- Available at: http://radiopaedia.org/articles/carcinoma-of-the-cervix. Accessed March 19, 2014.
- Nogueira-rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer. 2014;
- Available at: http://oncolex.org/en/Gynecological-cancer/Diagnoses/Cervical-cancer/Background/DifferentialDiagnoses. Accessed March 19, 2014.